Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: Studies of CDKN2A and other genes of the pRB pathway

Genes Chromosomes and Cancer

Volumn 26, Issue 2, 1999, Pages 151-160

  Berner, Jeanne Marie ^a   Sørlie, Therese ^a   Mertens, Fredrik ^b   Henriksen, Jørn ^a   Sæter, Gunnar ^a   Mandahl, Nils ^b   Brøgger, Anton ^a   Myklebost, Ola ^a   Lothe, Ragnhild A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; RETINOBLASTOMA PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME BAND; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PERIPHERAL NERVE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADOLESCENT; ADULT; AGED; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENES, P16; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUSCLE NEOPLASMS; NERVE SHEATH NEOPLASMS; RETINOBLASTOMA PROTEIN; SKIN NEOPLASMS;

EID: 0032879327     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A     Document Type: Article

References (49)

1. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. 1996. The p16-cyclin D/Cdk4-pRB pathway as a funtional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483.
2. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Van der Riet P, Blaugrund JE, Sidransky D. 1994. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-416.
3. 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 85:5259-5263.
4. Esteve A, Martel-Planche G, Sylla BS, Hollstein M, Hainaut P, Montesano R. 1996. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer 66:301-304.
5. Feinberg AP, Vogelstein B. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13.
6. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock D, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton A, Lahti J, Kidd VJ, Housman DE, Dracopoli NC. 1992. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557-10561.
7. Giercksky HE, Thorstensen L, Qvist H, Nesland JM, Lothe RA. 1997. Comparison of genetic changes in frozen biopsies and microdissected archival material from the same colorectal liver metastases. Diagn Molec Pathol 6:318-325.
8. Glover TW, Stein CK, Legius E, Andersen LB, Brereton A, Johnsen S. 1991. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer 3:62-70.
9. INK4B is a potential effector of TGF-ß-induced cell cycle arrest. Nature 371:257-260.
10. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
11. Huang L-S, Bock SC, Feinstein SI, Breslow JL. 1985. Human apolipoprotein B cDNA clone isolation and demonstration that liver apolipoprotein B mRNA is 22 kilobases in length. Proc Natl Acad Sci USA 82:6825-6829.
12. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark W, Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21.
13. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13:1065-1072.
14. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. 1992. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
15. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RSI, Johnson BE, Skolnick MH. 1994a. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
16. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA. 1994b. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:22-26.
17. Kovar H, Jug G, Aryee DNT, Zoubek A, Ambros P, Gruber B, Windhager R, Gadner H. 1997. Among genes involved in the RB dependent cell cycle regulatory cascade the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15:2225-2232.
18. Legius E, Marchuk DA, Collins FS, Glover TW. 1993. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3:122-126.
19. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, Glover TW. 1994. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 10:250-255.
20. Lothe RA. 1997. Microsatellite instability in human solid tumors. Mol Med Today 3:61-68.
21. Lothe RA, Slettan A, Sæter G, Brøgger A, Børresen AL, Nesland JM. 1995. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J Neuropathol Exp Neurol 54:65-73.
22. Lothe RA, Karhu R, Mandahl N, Mertens F, Sæter G, Heim S, Børresen-Dale A-L, Kallioniemi O-P. 1996. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res 56:4778-4781.
23. Maelandsmo GM, Berner J-M, Flørenes VA, Forus A, Hovig E, Fodstad Ø, Myklebost O. 1995. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas: relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 72:393-398.
24. INK4A transcript. Cancer Res 55:2995-2997.
25. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, Barker DF, Ledbetter DH, Kleider A, Martuza RL, Gusella JF, Seizinger BR. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 87:5435-5439.
26. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 1995. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692.
27. Mertens F, Rydholm A, Bauer HFC, Limon J, Nedoszytko B, Szadowska A, Willén H, Heim S, Mitelman F, Mandahl N. 1995. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer 61:793-798.
28. INK4A/CDKN2A/MTS1 mutations independent of p53 status in soft tissue sarcomas. J Pathol 184:14-17.
29. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708.
30. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
31. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
32. Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, Nobori T, Cowan JM, Rowley J, Diaz MO. 1992. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52:2523-2529.
33. Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD, Diaz MO. 1993. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53:2410-2415.
34. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C. 1995. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87:1524-1529.
35. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
36. Quelle DE, Zindy F, Ashmun RA, Sherr C. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
37. Riccardi VM. 1992. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore: Johns Hopkins University Press.
38. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. 1994. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321-6324.
39. Serrano M, Hannon GJ, Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
40. Skuse GR, Kosciolek BA, Rowley PT. 1989. Molecular genetic analysis in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. Genes Chromosomes Cancer 1:36-41.
41. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A. 1995. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988-2994.
42. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS. 1995. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893-901.
43. Su YA, Trent JM, Guan X-Y, Meltzer PS. 1994. Direct isolation of genes encoded within a homogeneously staining region by chromosome dissection. Proc Natl Acad Sci USA 91:9121-9125.
44. Tarkkanen M, Aaltonen LA, Böhling T, Kivioja A, Karaharju E, Elomaa I, Knuutila S. 1996. No evidence of microsatellite instablity in bone tumours. Br J Cancer 74:453-455.
45. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. 1996. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153.
46. Wooster R, Cleton-Jansen A-M, Collins N, Mangion J, Cornelis R, Cooper C, Gusterson B, Ponder B, von Deimling A, Wiestler O, Cornelisse C, Devilee P, Stratton M. 1994. Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet 6:152-156.
47. Xiong Y, Menninger J, Beach D, Ward DC. 1992. Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics 13:575-584.
48. Yao J, Pollock RE, Lang A, Tan M, Pister PWT, Goodrich D, El-Naggar A, Yu D. 1998. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res 4:1065-1070.
49. Zhang Y, Xiong Y, Yarbrought WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and the p53 tumor suppression pathways. Cell 92:725-734.